Mabpharm Ltd
02181
Company Profile
Business description
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.
Contact
Lujia Road East, Koutai Road West
Block G79, China Medical City
Taizhou225300
CHNT: +523 80660808
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
389
Stocks News & Analysis
stocks
Chip stock selloff deepens in Asia, extends to Europe and US
The week’s tech stock rout continues despite strong earnings from TSMC and ASML.
stocks
Downgrade for ASX listed fund manager as redemptions pile on
Persistent outflows erode earnings outlook.
stocks
Tesla stock is down nearly 20% rhis year. Is it a buy ahead of earnings?
Following the rollout of its first autonomous Cybercab, here’s what we expect from Tesla’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,916.60 | 76.20 | 0.86% |
| CAC 40 | 7,934.70 | 61.59 | 0.78% |
| DAX 40 | 25,382.62 | 84.01 | 0.33% |
| Dow JONES (US) | 52,177.69 | 556.21 | 1.08% |
| FTSE 100 | 10,840.35 | 115.49 | 1.08% |
| HKSE | 24,062.72 | 251.45 | -1.03% |
| NASDAQ | 26,713.03 | 20.16 | 0.08% |
| Nikkei 225 | 65,194.28 | 768.33 | 1.19% |
| NZX 50 Index | 13,787.39 | 45.41 | -0.33% |
| S&P 500 | 7,744.06 | 25.12 | 0.33% |
| S&P/ASX 200 | 8,788.50 | 68.80 | 0.79% |
| SSE Composite Index | 3,707.48 | 59.75 | -1.59% |